For patients with bladder cancer, invisible blood in urine may aid diagnosis
the ONA take:
According to new research published in the British Journal of General Practice, invisible blood in the urine may be able to be used to diagnose bladder cancer. Researchers at the University of Exeter Medical School in Exeter, United Kingdom, identified over 26,000 patients from the Clinical Practice Research Datalink and found that one in 60 patients over the age of 60 who had invisible blood in their urine were later diagnosed with bladder cancer.
The best known indicator of bladder cancer is visible blood in urine. Identifying invisible blood could boost early detection of bladder cancer, thereby improving outcomes compared with those who are diagnosed late.
According to the National Cancer Institute, if diagnosed with stage 1 bladder cancer, a patient has an 88% 5-year survival rate, but if diagnosed with stage 4 cancer, the 5-year survival rate drops to 15%.
The American Cancer Society says that nearly 75,000 Americans will be diagnosed with bladder cancer and about 16,000 will die from the disease in 2014. Bladder cancer is about three times more likely in men than women and occurs mainly in older adults.
Invisible blood in the urine may be able to be used to diagnose bladder cancer.
New research which finds that invisible blood in urine may be an early warning sign of bladder cancer is likely to shape guidelines for clinicians. Scientists at the University of Exeter Medical School found that one in 60 people over the age of 60 who had invisible blood in their urine (identified by their GP testing their urine) transpired to have bladder cancer.
The figure was around half those who had visible blood in their urine - the best known indicator of bladder cancer. However, it was still higher than figures for other potential symptoms of bladder cancer that warrant further investigation.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|